Cambridge Acquisition Corp. Class A Ordinary Shares (CAQ) vs Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)

A side-by-side comparison of Cambridge Acquisition Corp. Class A Ordinary Shares and Drugs Made In America Acquisition Corp. Ordinary Shares across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Cambridge Acquisition Corp. Class A Ordinary Shares logo
CAQ
Cambridge Acquisition Corp. Class A Ordinary Shares
$251M
$10.05Financial ServicesDelayed quote: Oct 6, 2026, 10:22 AM EDT
Drugs Made In America Acquisition Corp. Ordinary Shares logo
DMAA
Drugs Made In America Acquisition Corp. Ordinary Shares
$264M
$10.89Financial ServicesDelayed quote: Oct 6, 2026, 2:26 PM EDT

Total return — CAQ vs DMAA

growth of $100 · dividends reinvested · last 1y
CAQ +0.5% (+0.5%/yr)DMAA +3.9% (+3.9%/yr)DMAA compounded faster over this window
100102104Start $100$101$104
CAQ DMAA

CAQ vs DMAA: by the numbers

  • •DMAA is the larger company ($264M vs $251M market cap).

Metrics side by side

Valuation

MetricCAQDMAA
P/E ratioN/A55.48
P/B ratio1.111.92

Profitability

MetricCAQDMAA
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROEN/A4.42%
ROIC-93099.13%-1.82%

Go deeper

Full CAQ analysisFull DMAA analysisInteractive comparison tool

Dig into the metrics

Drugs Made In America Acquisition Corp. Ordinary Shares P/E ratioCambridge Acquisition Corp. Class A Ordinary Shares ROEDrugs Made In America Acquisition Corp. Ordinary Shares ROECambridge Acquisition Corp. Class A Ordinary Shares operating marginDrugs Made In America Acquisition Corp. Ordinary Shares operating marginCambridge Acquisition Corp. Class A Ordinary Shares revenue growthDrugs Made In America Acquisition Corp. Ordinary Shares revenue growthCambridge Acquisition Corp. Class A Ordinary Shares free cash flowDrugs Made In America Acquisition Corp. Ordinary Shares free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.